-

Shareholder Alert: Robbins LLP Announces Wins Finance Holdings Inc. (WINS) Accused of Misleading Shareholders

SAN DIEGO & BEIJING--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Wins Finance Holdings Inc. (NASDAQ: WINS) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between October 31, 2018 and July 6, 2020. Wins provides financing solutions for small and medium enterprises in the People's Republic of China.

If you suffered a loss as a result of Wins' misconduct, click here.

Wins Finance Holdings Inc. (WINS) Accused of Misleading Shareholders

According to the complaint, in 2014, Wins entered into a RMB 580 million credit arrangement with Guohong Asset Management Co., Ltd. ("Guohong") in which Guohong would be required to repay in October 2019. However, around the time the loan was to be repaid in October 2019, Wins filed a notification of inability to timely file its Form 20-F. Consequently, in November 2019, Wins disclosed that it had received a notification letter from the NASDAQ Listing Qualifications and revealed that Wins was unable to timely file its Form 20-F due to its inability to secure repayment of the RMB 580 million loan. However, Wins assured investors "the failure to collect this amount will not impact the Company’s ongoing operations." Despite assurances, on May 26, 2020, Wins revealed it had received a delisting determination letter from NASDAQ. Finally, on June 6, 2020, Wins disclosed its independent auditor had resigned, stating that the independent auditor "expressed an adverse opinion on the Company’s internal control over financial reporting as of June 30, 2017 and 2018 because of material weaknesses." On this news, Wins' stock price fell $2.06 per share, or 6%, to close at $31.70 per share. The stock continues to decline.

If you purchased Wins Finance Holdings Inc. (WINS) securities between October 31, 2018 and July 6, 2020, you have until September 23, 2020, to ask the court to be appointed lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Wins settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom